Welcome to the Jason Carter Clinical Trials Website
Our website helps patients find clinical trials. We currently offer patient-friendly descriptions of leukemia and lymphoma trials. Early in 2018, we will be:
Adding patient-friendly trial descriptions for other blood cancers and disorders
Making improvements to the search tool
Expanding our educational resources
Didn't find a trial or need help? Contact our clinical trial specialist at 888-814-8610 or contact@ctsearchsupport.org.
Introducing NMDP, formerly known as the National Marrow Donor Program and Be The Match. Our name has changed but our mission has not: We save lives through cell therapy. Learn More
Featured Trial
Allogeneic (cells from a donor) blood or marrow transplant (BMT) or immunosuppressive therapy to treat severe aplastic anemia (SAA) that has not yet been treated in children, teens and young adults (TransIT, BMT CTN 2202)
To find out whether allogeneic BMT or immunosuppressive therapy is more effective in treatment of SAA that has not yet been treated in children, teens and young adults
You may be able to join this trial if you:
You or your child:
Is 25 years old or younger
Has SAA
Has two bone marrow donor matches on the public registry
Does not have a family member who is their full match and can be their stem cell donor
Does not have dyskeratosis congenita, Fanconi anemia, Shwachman-Diamond syndrome or other forms of inherited (genetic) marrow failure syndromes
Has not had a BMT
You agree to have other standard tests done to see if your child can be in the clinical trial
Trial Details
Anti-thymocyte globulin (ATG) and cyclosporine are standard drugs used to prevent graft-versus-host disease (GVHD) or to slow down the immune system. Cyclophosphamide and fludarabine are chemotherapy (chemo) drugs that slow down the immune system. Methotrexate is a chemo drug that prevents GVHD.
In this trial, you or your child will be randomized to 1 of 2 groups. Once randomized, you or your child will be told what group you/they're in:
Group 1 – Standard immunosuppressive therapy
Group 2 – Unrelated allogeneic BMT
Randomized means doctors will use a computer to assign you or your child to either group. A computer assigns by chance, like flipping a coin or drawing a name out of a hat. You, your child's doctor or the clinical trial doctor won’t have any control over which group is assigned. This means you won’t be able to choose you o your child's group.
In Group 1, you or your child will get standard immunosuppressive therapy with:
Cyclosporine - A pill taken by mouth
ATG – Given as intravenous (IV) infusions
In Group 2, you or your child will get an allogeneic BMT.
First, you/they will get:
ATG - Given as IV infusions
Cyclophosphamide – Given as IV infusions
Fludarabine – Given as IV infusions
Total body irradiation (TBI) – A treatment done 1 time to prepare the body for transplant
On transplant day, the blood-forming cells from you or your child's donor are given through an IV infusion.
After transplant, you or your child will get:
Cyclosporine – Given as IV infusions
Methotrexate – Given as IV infusions
You or your child may continue treatment for as long as the clinical trial doctors think it’s best for your/their health. Biopsies will be done to see how well the treatment is working. The clinical trial doctors will check you or your child's health for up to 5 years.
The Food and Drug Administration (FDA) has approved allogeneic BMT and all of the drugs used in this trial.
collaborator: Center for International Blood and Marrow Transplant Research, collaborator: National Institutes of Health (NIH), collaborator: National Heart, Lung, and Blood Institute (NHLBI), collaborator: North American Pediatric Aplastic Anemia Consortium, collaborator: Pediatric Transplantation and Cellular Therapy Consortium, collaborator: Blood and Marrow Transplant Clinical Trials Network, lead: Boston Children's Hospital